Donepezil Derivatives Targeting Amyloid-beta Cascade in Alzheimer's Disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F19%3A00537472" target="_blank" >RIV/60162694:G44__/19:00537472 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/62690094:18470/19:50016115 RIV/00179906:_____/19:10402691

Výsledek na webu

<a href="http://www.eurekaselect.com/170311/article" target="_blank" >http://www.eurekaselect.com/170311/article</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2174/1567205016666190228122956" target="_blank" >10.2174/1567205016666190228122956</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Donepezil Derivatives Targeting Amyloid-beta Cascade in Alzheimer's Disease

Popis výsledku v původním jazyce

Alzheimer's Disease (AD) is a neurodegenerative disorder with an increasing impact on society. Because currently available therapy has only a short-term effect, a huge number of novel compounds are developed every year exploiting knowledge of the various aspects of AD pathophysiology. To better address the pathological complexity of AD, one of the most extensively pursued strategies by medicinal chemists is based on Multi-target-directed Ligands (MTDLs). Donepezil is one of the currently approved drugs for AD therapy acting as an acetylcholinesterase inhibitor. In this review, we have made an extensive literature survey focusing on donepezil-derived MTDL hybrids primarily targeting on different levels cholinesterases and amyloid beta (A beta) peptide. The targeting includes direct interaction of the compounds with A beta, AChE-induced A beta aggregation, inhibition of BACE-1 enzyme, and modulation of biometal balance thus impeding A beta assembly.

Název v anglickém jazyce

Donepezil Derivatives Targeting Amyloid-beta Cascade in Alzheimer's Disease

Popis výsledku anglicky

Alzheimer's Disease (AD) is a neurodegenerative disorder with an increasing impact on society. Because currently available therapy has only a short-term effect, a huge number of novel compounds are developed every year exploiting knowledge of the various aspects of AD pathophysiology. To better address the pathological complexity of AD, one of the most extensively pursued strategies by medicinal chemists is based on Multi-target-directed Ligands (MTDLs). Donepezil is one of the currently approved drugs for AD therapy acting as an acetylcholinesterase inhibitor. In this review, we have made an extensive literature survey focusing on donepezil-derived MTDL hybrids primarily targeting on different levels cholinesterases and amyloid beta (A beta) peptide. The targeting includes direct interaction of the compounds with A beta, AChE-induced A beta aggregation, inhibition of BACE-1 enzyme, and modulation of biometal balance thus impeding A beta assembly.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30210 - Clinical neurology

Projekt

<a href="/cs/project/NV15-30954A" target="_blank" >NV15-30954A: Vývoj multifunkčního léčiva na Alzheimerovu nemoc: kombinace inhibitoru AChE a derivátu melatoninu</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Alzheimer Research

ISSN

1567-2050

e-ISSN

1875-5828

Svazek periodika

16

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

AE - Spojené arabské emiráty

Počet stran výsledku

29

Strana od-do

772-800

Kód UT WoS článku

000493721100002

EID výsledku v databázi Scopus

2-s2.0-85072308142